Autopsy and Case Reports
Autopsy and Case Reports
Article / Clinical Case Report

Acquired hemophilia A in a patient with advanced prostate cancer

Daniel da Motta Girardi; Douglas Rafael Almeida Silva; Paula Ribeiro Villaça; Ciro Eduardo Souza; Leonardo Gomes da Fonseca; Diogo Assed Bastos; Paulo Marcelo Gehm Hoff

Downloads: 7
Views: 1253


Acquired hemophilia A (AHA) is a rare disorder that results from the presence of autoantibodies against the clotting factor VIII (FVIII) causing hemorrhagic disorders. This entity is mostly associated with autoimmune diseases, pregnancy, the postpartum period, drugs and malignancy. Among the solid cancers, prostate neoplasm is the most common cause of AHA. The management of AHA involves the control of active bleeding and the use of specific therapies to eliminate the inhibitor. The authors describe the case of an 87-year-old man with prostate cancer who developed a bleeding disorder 5 years after the cancer diagnosis. Treatment with prednisone did not reach a satisfactory clinical response, which was only achieved with the association of azathioprine. The patient became asymptomatic with no further bleeding episodes, but developed a fatal sepsis after 3 months of treatment with these immunosuppressive agents.


Factor 8 deficiency, acquired, Prostatic Neoplasm, Hemorrhage


Franchini M, Gandini G, Di Paolantonio T, Mariani G. Acquired hemophilia A: a concise review. Am J Hematol. 2005;80(1):55-63. []. [PMID:16138334]

Knoebl P, Marco P, Baudo F, et al. Demographic and clinical data in acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2). J Thromb Haemost. 2012;10(4):622-31. []. [PMID:22321904]

Sallah S, Wan JY. Inhibitors against factor VIII in patients with cancer. Analysis of 41 patients. Cancer. 2001;91(6):1067-74. [<1067::AID-CNCR1101>3.0.CO;2-4]. [PMID:11267950]

Reeves BN, Key NS. Acquired hemophilia in malignancy. Thromb Res. 2012;129(Suppl 1):S66-8. []. [PMID:22682137]

Bitting RL, Bent S, Li Y, Kohlwes J. The prognosis and treatment of acquired hemophilia: a systematic review and meta-analysis. Blood Coagul Fibrinolysis. 2009;20(7):517-23. []. [PMID:19644360]

Shetty S, Bhave M, Ghosh K. Acquired hemophilia a: diagnosis, aetiology, clinical spectrum and treatment options. Autoimmun Rev. 2011;10(6):311-6. []. [PMID:21115138]

Collins PW, Hirsch S, Baglin TP, et al. Acquired hemophilia A in the United Kingdom: a 2-year national surveillance study by the United Kingdom Haemophilia Centre Doctors’ Organisation. Blood. 2007;109(5):1870-7. []. [PMID:17047148]

Delgado J, Jimenez-Yuste V, Hernandez-Navarro F, Villar A. Acquired haemophilia: review and meta-analysis focused on therapy and prognostic factors. Br J Haematol. 2003;121(1):21-35. []. [PMID:12670328]

Franchini M, Targher G, Montagnana M, Lippi G. Laboratory, clinical and therapeutic aspects of acquired hemophilia A. Clin Chim Acta. 2008;395(1-2):14-8. []. [PMID:18505682]

Hauser I, Lechner K. Solid tumors and factor VIII antibodies. Thromb Haemost. 1999;82(3):1005-7. [PMID:10494753]

Huth-Kühne A, Baudo F, Collins P, et al. International recommendations on the diagnosis and treatment of patients with acquired hemophilia A. Haematologica. 2009;94(4):566-75. []. [PMID:19336751]

W Collins P, Chalmers E, Hart D, et al. Diagnosis and management of acquired coagulation inhibitors: a guideline from UKHCDO. Br J Haematol. 2013;162(6):758-73. []. [PMID:23889317]

Baudo F, Collins P, Huth-Kühne A, et al. Management of bleeding in acquired hemophilia A: results from the European Acquired Haemophilia (EACH2) Registry. Blood. 2012;120(1):39-46. []. [PMID:22618709]

Collins P, Baudo F, Knoebl P, et al. Immunosuppression for acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2). Blood. 2012;120(1):47-55. []. [PMID:22517903]


Publication date:

569538fa64cc8b1a57053d87 autopsy Articles

Autops Case Rep

Share this page
Page Sections